PERSISTENCE, COMPLIANCE AND BISPHOSPHONATE SWITCHING IN PATIENTS WITH MULTIPLE MYELOMA (MM) IN GERMANY

Author(s)

Intorcia M¹, Ansorge S², Giannopoulou C¹, Hohmann D³
¹Amgen GmbH, Zug, Switzerland, ²arvato health analytics, Munich, Germany, ³Amgen GmbH, Munich, Germany

OBJECTIVES: This retrospective observational analysis aimed to estimate persistence, compliance and switch patterns in MM patients newly treated with bisphosphonates (BPs) approved in Germany for the prevention of SREs METHODS: This was a retrospective analysis of German health insurance claims data (including ~4 million patients). The study included newly diagnosed MM patients aged ≥18 with no prior hypercalcemia, undergoing BP treatment for the first time. Descriptive analyses to estimate persistence, compliance and switch rate among first line intravenous BP treatments were performed. Persistence was defined as continuous prescriptions with <90-days gaps. Compliance was defined as ≥12 prescriptions within 12 months after BP initiation. A switch was defined as a change from a prescribed BP to another BP within a <90-day window. Patients were censored at death.

RESULTS: The sample included 281 patients (female: 53.0%, mean age: 68.1 [SD 11.2], previous SRE: 31.7%, renal disease: 19.9%). In the first year, BP compliance rates were 35.7% and 28.0% for pamidronate and zoledronate, respectively. Persistence rates [%(95% CI)] at 12 months were 50.9% (44.7-58.0) overall, 52.8% (37.6-74.0) for ibandronate, 44.2% (36.4-53.7) for pamidronate, and 48.4% (37.0-63.2) for zoledronate. Median time to non-persistence [median (95% CI)] after treatment initiation was 53 weeks (40-76) overall, 55 (31-NA) for ibandronate, 45 (28-82) for pamidronate and 41 (32-65) for zoledronate. The switch rates from ibandronate, pamidronate and zoledronate to another BP were 9.8%, 12.5% and 4.8% for ibandronate, pamidronate and zoledronate, respectively

CONCLUSIONS: In MM patients treated with BPs, persistence at 12 months was 50.9%. Compliance was very low: at 12 months only 1 in 3 and 1 in 4 patients had received ≥12 prescriptions of pamidronate and zoledronate respectively. Between 5% and 12% switched treatments within the first 12 months. Overall, patients with MM seem to be sub-optimally treated for the prevention of SREs

Conference/Value in Health Info

2017-11, ISPOR Europe 2017, Glasgow, Scotland

Value in Health, Vol. 20, No. 9 (October 2017)

Code

PCN284

Topic

Health Service Delivery & Process of Care

Topic Subcategory

Hospital and Clinical Practices, Prescribing Behavior, Treatment Patterns and Guidelines

Disease

Musculoskeletal Disorders, Oncology

Explore Related HEOR by Topic

Healthcare Delivery

Presentation